Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide-Reference-Cited by-同舟云学术

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide

Published:2016-08-18 Issue:12 Volume:30 Page:2405-2409
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Negoro E,Radivoyevitch T,Polprasert C,Adema V,Hosono N,Makishima H,Przychodzen B,Hirsch C,Clemente M J,Nazha A,Santini V,McGraw K L,List A F,Sole F,Sekeres M A,Maciejewski J P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2016228.pdf

Reference15 articles.

1. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.

2. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86–93.

3. Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008; 26: 5943–5949.

4. Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008; 5: e35.

5. Santini V, Almeida A, Giagounidis A, Gropper S, Jonasova A, Vey N et al. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. J Clin Oncol 2016; 34: 2988–2996.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of reactive oxygen species in myelodysplastic syndromes;Cellular & Molecular Biology Letters;2024-04-14

2. Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations;Hematology;2024-04-10

3. Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia;Biomedicines;2023-12-27

4. Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era;Blood Reviews;2023-11

5. Venetoclax plus hypomethylating agents in DDX41‐mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients;British Journal of Haematology;2023-09-14